

News Release

January 28, 2026

Patent Grant for the Therapeutic Use of UC-MSC in Sarcopenia

– Aiming to Develop Cell Therapy for Sarcopenia Based on the Outcomes of Academia–Industry Collaborative Research –

Human Life CORD Japan Inc. (Head Office: Chuo-ku, Tokyo; President & CEO: Masamitsu Harata; hereinafter “HLC”), a company pioneering the practical application and global deployment of umbilical cord–derived mesenchymal stromal cells (UC-MSCs) as regenerative medicine products, hereby announces that it has been granted a patent in Japan for a technology related to the therapeutic use of UC-MSCs for sarcopenia.

This patent is based on research outcomes obtained through an academia–industry collaborative research program, “Human Life CORD Applied Cellular Medicine Program (September 2019 – March 2022)”, conducted jointly with the Nagoya University Graduate School of Medicine (hereinafter “Nagoya University”).

Sarcopenia is a disease characterized by age-related loss of skeletal muscle mass, accompanied by declines in muscle strength and physical function. Through collaborative research with Nagoya University, UC-MSCs were shown to suppress muscle mass loss in accelerated aging model animals.

Based on these research outcomes, the patent covers a cell preparation composed of UC-MSCs intended for the suppression of muscle mass decline. This patent constitutes an important intellectual property foundation for expanding the application of UC-MSCs in the field of regenerative medicine to sarcopenia and other age-related diseases.

Comment from Dr. Masafumi Kuzuya

Director, Meitetsu Hospital

Former Professor, Department of Geriatrics, Graduate School of Medicine, Nagoya University

Sarcopenia, characterized by a reduction in skeletal muscle mass and muscle strength, is closely associated with physical functional decline and frailty in older adults and represents a major factor limiting the extension of healthy life expectancy. As the global elderly population continues to increase, addressing sarcopenia has become an urgent challenge not only in Japan but also internationally.

To date, primary interventions have focused on promoting physical activity, appropriate nutritional intake, and

social participation. In this context, the cell therapy strategy for sarcopenia using UC-MSCs represent a novel and proactive therapeutic approach, and its future development is highly anticipated.

Leveraging this patent grant, HLC will further advance research and development of regenerative medicine products utilizing UC-MSCs in the field of sarcopenia and other age-related diseases.

In addition, patent applications related to this technology are currently pending in the United States and Europe. With a view toward developing UC-MSC-based cell therapy for sarcopenia in the Americas, HLC is accelerating its global expansion, including clinical research in Brazil and the establishment of a manufacturing framework through Japan–U.S. collaboration with New York Blood Center Enterprises.

Through these efforts, HLC aims to implement its established technologies as medical solutions in society and to realize a world where “growing older is more enjoyable.”

Patent Information

- **Patent Number:** JP Patent No. 7803543
 - **Title of Invention:** Cell Preparation for Suppressing Muscle Mass Decline
 - **Date of Registration:** January 13, 2026
 - **Patent Holder:** Human Life CORD Japan Inc.
-

About Human Life CORD Japan Inc.

(<https://humanlifecord.com>)

Human Life CORD Japan Inc, Inc. develops and manufactures umbilical cord-derived cell products that can be domestically sourced and cryopreserved in Japan. Our mission is to transform umbilical cords—often discarded after birth—into sources of life-saving cell therapies for patients with unmet medical needs, and eventually into preventive medicine that extends healthy life expectancy. Awards include: Tokyo Venture Championship Grand Prize & Governor of Tokyo Award (2019), Japan Open Innovation Award – Minister of Health, Labour and Welfare Award (2023), J-Startup selected company (2023), and the Tokyo Chamber of Commerce and Industry “Courageous Management Award” – Startup Division Grand Prize (2024).

[Contact for Media Inquiries]

Public Relations, Human Life CORD Japan Inc.

Attn: Yuki Hayashi

TEL: +81-80-4671-0405

Email: info@humanlifecord.com